See the Complete Picture.
Published loading...Updated

There Could Soon Be a Botox That Smooths Lines Same-Day

  • AbbVie submitted a Biologics License Application to the FDA in 2025 for TrenibotE, a new neuromodulator to treat moderate to severe glabellar lines.
  • AbbVie developed TrenibotE after extensive Phase 3 trials with over 2,100 patients, aiming for faster effects as early as eight hours post-injection.
  • Dermatologists and experts, including trial investigator Ava Shamban, expect FDA approval possibly by late 2025 or early 2026, though AbbVie declined to comment on timing or pricing.
  • New NMC guidance mandates that nurse prescribers must conduct face-to-face consultations before prescribing non-surgical cosmetic medicines, aiming to end unsafe remote prescribing practices.
  • This regulation change responds to rising cosmetic procedure popularity and safety concerns, signaling stronger public protection and tightening UK sector oversight starting June 2025.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
Center
1
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Stv broke the news in Scotland, United Kingdom on Tuesday, April 29, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.